慢性肾脏病相关瘙痒:诊断、发病机制与管理的新见解
慢性肾脏病相关瘙痒(CKD-aP)在CKD中患病率约20%、终末期肾病中约40%,与较差的心理社会和医疗结局明确相关,但常被患者低估和医生忽视。其发病机制多归因于毒素蓄积、周围神经病变、免疫失调或阿片系统失调。近期针对阿片系统失调的大型随机对照试验取得有希望的结果,为理解和治疗该病带来新希望。
要点
- CKD-aP在CKD中患病率约20%,在终末期肾病中约40%。
- 该病常被患者低估报告并被医护人员忽视。
- 近期针对阿片系统失调的大型随机对照试验结果有希望。
核心结论
- CKD-aP是常见且困扰CKD及终末期肾病患者的病症,与较差的心理社会和医疗结局明确相关。
- 尽管患病率较高,该病常被患者低估报告并被医护人员忽视。
研究设计与样本
- 综述性文章,总结CKD-aP的诊断、发病机制与管理的新见解。
主要发现
- CKD-aP在CKD中患病率约20%,在终末期肾病中约40%。
- CKD-aP常被归因于毒素蓄积、周围神经病变、免疫系统失调或阿片系统失调。
- 既往治疗研究受限于非对照设计、样本量小及CKD-aP定义不统一。
- 近期针对阿片系统失调的大型随机对照试验取得有希望的结果。
临床怎么用
- 临床应提高对CKD-aP的识别,避免忽视患者报告的症状。
- 关注针对阿片系统失调的新治疗证据。
局限性
- CKD-aP发病机制和治疗存在不确定性。
- 既往治疗研究受限于非对照设计、样本量小及定义不统一。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic kidney disease-associated pruritus (CKD-aP) is a common, troubling and in some cases debilitating problem for patients with CKD and end-stage renal disease. Despite a prevalence rate of approximately 20% in CKD and 40% in end-stage renal disease, and a clear association with poorer psychosocial and medical outcomes, this condition is often underreported by patients and overlooked by health care providers. This is likely due, in part, to uncertainty regarding its pathogenesis and treatment. Most commonly, CKD-aP is attributed to toxin build-up, peripheral neuropathy, immune system dysregulation, or opioid dysregulation. Prior treatment studies of CKD-aP have targeted these potential etiologies but have been limited by noncontrolled design, small sample size, and non-uniform definitions of CKD-aP. Recently, several large, randomized controlled trials targeting opioid dysregulation have yielded promising results. These trials have spurred new hope for understanding and treating this condition.
引用
- Verduzco HA, Shirazian S. CKD-Associated Pruritus: New Insights Into Diagnosis, Pathogenesis, and Management. Kidney Int Rep. 2020. PMID: 32954065. doi:10.1016/j.ekir.2020.04.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。